BioMarin (BMRN) announced positive new data from studies of Voxzogo in children with achondroplasia and in ongoing clinical trials ...

SAN RAFAEL, Calif., Feb. 24, 2025 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced that the company has appointed Timothy P. Walbert, former chairman, president and ...

Oppenheimer upgraded BioMarin (BMRN) to Outperform from Perform with a $98 price target See what stocks are receiving strong buy ratings from top-rated analysts. Filter, analyze, and streamline ...

Oppenheimer upgrades BioMarin on long term outlook Amgen India opens with $200 million investment plan through 2025 National Grid sells $1.7 billion US renewables arm to Brookfield ...

BioMarin Pharmaceutical has a twelve month low of $60.63 and a twelve month high of $94.85. The stock has a market cap of $13.56 billion, a price-to-earnings ratio of 32.35, a P/E/G ratio of 0.61 ...

BioMarin Pharmaceutical Stock Up 0.1 % BMRN opened at $70.60 on Friday. The firm has a 50 day moving average price of $66.16 and a 200 day moving average price of $69.10. The company has a market ...

BioMarin Pharmaceutical (Nasdaq: BMRN) reported $747.31 million in revenue for the fourth quarter, a 16% year-over-year increase. The San Rafael-based global producer of genetic treatments for ...

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN), a biotechnology company specializing in therapies for rare genetic diseases with a market capitalization of $13.15 billion, has been navigating a ...

The new logo of the Manila International Airport Authority comes as the agency transitions from being operator to regulator of the Ninoy Aquino International Airport CEBU, Philippines – The ...